PBLS
Income statement / Annual
Last year (2025), Parabilis Medicines Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Parabilis Medicines Inc.'s net income was -$145.89 M.
See Parabilis Medicines Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
| Period Ended |
12/31/2025 |
12/31/2024 |
| Operating Revenue |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
| Research and Development Expenses |
$125.58 M
|
$100.83 M
|
| General & Administrative Expenses |
$26.50 M
|
$25.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.50 M
|
$25.30 M
|
| Other Expenses |
$0.00
|
$0.00
|
| Operating Expenses |
$152.08 M
|
$126.13 M
|
| Cost And Expenses |
$152.08 M
|
$126.13 M
|
| Interest Income |
$3.39 M
|
$6.41 M
|
| Interest Expense |
$1.52 M
|
$1.49 M
|
| Depreciation & Amortization |
$2.50 M
|
$2.10 M
|
| EBITDA |
-$141.87 M |
-$114.33 M |
| EBITDA Ratio |
0
|
0
|
| Operating Income Ratio |
0
|
0
|
| Total Other Income/Expenses Net |
$6.19 M
|
$8.21 M
|
| Income Before Tax |
-$145.89 M
|
-$117.91 M
|
| Income Before Tax Ratio |
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
| Net Income |
-$145.89 M
|
-$117.91 M
|
| Net Income Ratio |
0
|
0
|
| EPS |
-92.4 |
-83.48 |
| EPS Diluted |
-92.4 |
-83.48 |
| Weighted Average Shares Out |
$2.02 M
|
$1.93 M
|
| Weighted Average Shares Out Diluted |
$2.02 M
|
$1.93 M
|
| Link |
|
|
